Clin2
NCT06993233Possibly a fitRecruiting

Study of CIT-013 for hidradenitis suppurativa

Hidradenitis Suppurativa (HS)

Treatments studied

Part of Infections, Skin clinical trials.

This trial tests a new medication called CIT-013 for people with moderate to severe hidradenitis suppurativa (HS) who have not had enough relief from oral antibiotics. The goal is to see if this treatment can reduce painful bumps and abscesses.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
96 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have had HS for more than 6 months
  • You are 18 years or older
  • You have HS bumps in at least 2 different body areas, with at least one area being stage II or III (moderate to severe)
  • You currently have at least 5 inflamed bumps or abscesses
  • Oral antibiotics haven't worked well enough, or you can't take them
  • You have fewer than 20 draining tunnels (tracts under the skin)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07244510Recruiting· Phase 2
New Treatment for Moderate to Severe Hidradenitis Suppurativa

This trial tests a new medicine called SCT650C for people with moderate to severe hidradenitis suppurativa (HS). The goal is to see if it can reduce painful bumps and abscesses better than current treatments.

Samsun, Turkey
NCT06932003Recruiting· Phase 1/Phase 2
Testing a new tablet for hidradenitis suppurativa

This trial is testing an experimental tablet called LT-002-158 in adults with moderate to severe hidradenitis suppurativa (HS) that hasn't improved enough with standard treatments. The goal is to see if it's safe and helps reduce painful lumps and abscesses.

Beijing, Beijing Municipality
NCT07766005Not yet recruiting· Phase 2
Study of a new medicine for hidradenitis suppurativa

This trial tests an investigational medicine, SPY072, for adults with moderate to severe hidradenitis suppurativa (also known as HS), a skin condition that causes painful lumps and sores. If you join, you'll help see if this treatment is safe and effective.

Irvine, California
NCT07388446Not yet recruiting
MAIT cells in hidradenitis suppurativa study

This trial looks at a type of immune cell (MAIT cells) in people with hidradenitis suppurativa (a skin condition causing painful bumps). It aims to understand how these cells work and how they relate to treatments like adalimumab, secukinumab, or bimekizumab. You may be able to join if you have moderate-to-severe HS and are about to start one of these treatments.

Lyon
NCT07384975Recruiting· Phase 2
New drug NAV-240 for hidradenitis suppurativa

This trial tests a new drug called NAV-240 for people with hidradenitis suppurativa (HS) who have not had success with antibiotics. The goal is to see if the drug can reduce the number of painful lumps and improve symptoms.

Phoenix, Arizona
NCT06645821Recruiting· Early Phase 1
Cream for mild to moderate hidradenitis suppurativa

This trial tests a new cream (EVO101) for people with mild to moderate hidradenitis suppurativa (HS), a skin condition causing painful lumps. It aims to see if the cream can reduce the number of lesions. Participants cannot use certain other HS treatments during the study.

Norfolk, Virginia

Hear when a new Hidradenitis Suppurativa (HS) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.